[501] in peace2
Drug Companies' Tests in Poor Countries Raise Ethical Questions
daemon@ATHENA.MIT.EDU (felixauyeung@juno.com)
Mon Dec 18 18:33:20 2000
From: felixauyeung@juno.com
To: peace-list@mit.edu
Cc: clayadler@hotmail.com, jshulman@fas.harvard.edu,
brianerobinson@hotmail.com, erika@public.bta.net.cn,
elder@sinosphere.com, papouse@hotmail.com, tofudru@hotmail.com,
AnniqueClaussen@gmx.de, bammann@presidiotrust.gov,
crazedpsycho@usa.net, DBowermaster@strykerendo.com,
esther_luo@hotmail.com, JulianeTeller@gmx.de, katschoen@yahoo.com,
kimcharla@hotmail.com, kwittmann@yahoo.com, maisiechui@hotmail.com,
coccidia@hotmail.com, nkirchen@aecom.yu.edu,
tauyeun@muse.sfusd.k12.ca.us, wauyeung@stanford.edu,
stacesam@hotmail.com, laswaigas@usa.net
Date: Tue, 19 Dec 2000 00:32:18 +0800
Message-ID: <20001219.073536.-218735.0.felixauyeung@juno.com>
MIME-Version: 1.0
Content-Type: text/plain
Content-Transfer-Encoding: 7bit
Drug Companies' Tests in Poor Countries Raise Ethical Questions
Joe Stephens
Washington Post Service
Monday, December 18, 2000
Some Risky Experiments Are Done With Little Oversight
KANO, Nigeria By the time word of the little girl's death reached the
United States, her name had been replaced by numerals: No. 6587-0069.
.
She was 10 years old and a scant 41 pounds (18.6 kilograms). She lived in
Nigeria, and in April 1996 she ached from meningitis.
.
An epidemic raged and scores lay dying in this frenetic city of amber
dust. Somehow the girl found a refuge: a medical camp where foreign
doctors had arrived to dispense expensive medicines for free.
.
Behind a gate besieged by suffering crowds stood two very different
clinics. A humanitarian charity, Medecins Sans Frontieres, had erected a
treatment center solely in an effort to save lives. Researchers for
Pfizer Inc., a huge American drug company, had set up a second center.
They were using Nigeria's meningitis epidemic to conduct experiments on
children with what Pfizer believed was a promising new antibiotic - a
drug not yet approved in the United States.
.
The experimental drug was a potential blockbuster: Wall Street analysts
said Pfizer might reap $1 billion a year if Trovan, as it was known, won
approval for all its potential uses. Pfizer also wanted to test the drug
for use against meningitis, including an epidemic strain. The company
could not find enough patients in the United States, so its researchers
had come to Kano, among the dying.
.
Doctors working with Pfizer drew spinal fluid from the girl, gauged her
symptoms and logged her as Patient No. 0069 at Testing Site No. 6587 in
Experiment No. 154-149. They gave her 56 milligrams of Trovan.
.
A day later, the girl's strength was evaporat- ing, Pfizer records show,
and one of her eyes froze in place. On the third day, she died.
.
Pfizer records are explicit. Action taken: "Dose continued unchanged."
Outcome: "Death."
.
Nobody can know for certain if the girl would have lived had she been
taken off experimental Trovan; perhaps she was beyond all hope. Yet the
circumstances of her death - while taking an unapproved drug, with
alternative treatments at hand, in a hurriedly established private-sector
experiment - suggest much larger problems.
.
A Washington Post investigation into corporate drug experiments in
Africa, Asia, Eastern Europe and Latin America reveals a booming, poorly
regulated testing system that is dominated by private interests and that
far too often betrays its promises to patients and consumers.
.
Experiments involving risky drugs proceed with little independent
oversight. Impoverished, poorly educated patients are sometimes tested
without understanding that they are guinea pigs. And pledges of quality
medical care sometimes prove fatally hollow, The Post found.
.
Drugmakers hop borders with scant government review. Largely uninspected
by the U.S. Food and Drug Administration - which has limited authority
and few resources to police experiments overseas - U.S.-based drug
companies are paying doctors to test thousands of human subjects in the
Third World and Eastern Europe.
.
The companies use the tests to produce new products and new revenue
streams, but they are also responding to pressure from regulators,
Congress and lobbyists for disease victims to develop new medicines
quickly. By providing huge pools of human subjects, foreign trials help
speed new drugs to the marketplace - where they will be sold mainly to
patients in wealthy countries.
.
The Food and Drug Administration requires that patients in such tests, no
matter where they live, consent fully to the experiments if the results
are to be used to win marketing approval in the United States. And, in
fact, many tests conducted in the Third World are conducted carefully and
serve to expedite the creation of lifesaving drugs. But The Post's
investigation found that in other instances the rules are poorly enforced
or ignored.
.
The experiments raise questions about corporate ethics and profits on a
frontier of globalization where drug companies wield enormous influence,
and where doctors paid by U.S.-based corporations sometimes perform
experiments on ill-informed patients in authoritarian societies.
.
A Nigerian physician who said he was present during the Kano experiment,
for instance, felt it was "a bad thing," but he did not object because
Pfizer's test appeared to have government backing.
.
"I could not protest," said the physician, Amir Imam Yola. "The system
you have in America and the system we have here, there is a wide gap.
Freedom of speech is still not here."
.
Industry guidelines for conducting meningitis experiments never
envisioned testing an antibiotic amid a terrible epidemic in a squalid,
short-staffed medical camp lacking basic equipment.
.
Dr. George McCracken, a Texas pediatrician and leading meningitis
specialist who co-authored the guidelines, said he was surprised that
Pfizer's researchers had attempted such a venture. "I just wouldn't do a
study that way myself," he said. "I know they wanted to get the data.
They wanted to go fast. They wanted to move ahead. I'm not sure they made
a smart decision."
.
Among the 200 stricken children enrolled in its experiment, 11 died and
others suffered meningitis-related symptoms such as deafness, lameness,
blindness, seizures and, in one case, an inability to walk or talk,
company records show.
.
Pfizer said its goal was to study the safety and effectiveness of its
antibiotic while simultaneously pioneering a breakthrough treatment for
the Third World. The company contends that its practices were validated -
especially given the horrendous conditions it found - by the number of
children who showed improvement and by a fatality rate of about 6
percent, which compares favorably with those reported for bacterial
meningitis victims treated at U.S. hospitals. The Trovan experiment, a
company spokeswoman said, was approved by a Nigerian ethics board and
"was sound from medical, scientific, regulatory and ethical standpoints."
.
Pfizer researchers prepared the study over six weeks, instead of the year
or longer common in the United States. And while American meningitis
patients generally receive fast-acting intravenous medicines, the
researchers gave most of the Nigerian subjects an oral form of Trovan
that the company said had never been tested in children.
.
Ten doctors interviewed about Patient 0069's death - including
pediatricians, meningitis specialists and physicians who have practiced
in developing countries - said they were troubled by her case. Their
questions focused in part on whether doctors left her on the test drug
for too long as her health declined. Generally, if subjects are not
responding to an experimental treatment, they are removed from the test
and given proven medicines.
.
Industry guidelines governing meningitis experiments urge that
researchers conduct a second spinal tap a day or so after treatment
begins, to see if the medication is working. Pfizer researchers chose to
make such exams optional in Nigeria, and Pfizer said they did not perform
one on Patient 0069, leaving her on the experimental drug until her
death.
.
"It could be considered murder," said Evariste Lodi, the Medecins Sans
Frontieres physician who led the charity's efforts against meningitis in
Kano, after he reviewed a Pfizer description of Patient 0069's death.
Added Agwu Urondu, a Nigerian physician still working in the city: "The
patient died because the doctor refused to help."
.
In a written statement, a Pfizer spokeswoman said a death such as Patient
0069's could occur during treatment with any antibiotic and that
researchers had no reason to suspect the experimental medicine was not
working.
.
Abdulhamid Isa Dutse, a Nigerian doctor hired by Pfizer to run the
experiment, agreed that physicians should alter the medication of a
patient who is not improving. "To be very, very honest, in retrospect,
maybe we should have done something about that," he said of the girl.
.
Dr. Yola and others who battled the epidemic said patients did not
understand they had been in an experiment. "The patients did not know if
it was research or not," agreed a Nigerian laboratory technician who took
part. "They just knew they were sick."
.
Pfizer disputes that, saying that local nurses explained the research to
families, even though the company has no signed consent forms to prove
it.
.
Although Pfizer eventually won approval to sell the drug to adults in the
United States, in the end its push to bring Trovan to market turned out
badly. Authorities never approved marketing the antibiotic for use by
children in the United States or Nigeria. U.S. regulators discovered
dozens of discrepancies in the Kano test results. Last year, they advised
doctors to restrict Trovan's use in adults because patients had suffered
liver damage and death. European regulators suspended sales altogether.
.
Pfizer's Nigerian clinic opened and closed in a relative eye blink: About
three weeks after the company's team roared in with a chartered DC-9, the
team roared out. Pfizer's doctors returned once to examine the patients
but did not track their long-term recovery.
.
"If I had the power," said Dr. Lodi, who watched the experiment unfold
from across the compound, "I would take away their medical licenses."
***
FAY: just _raises_ ethical questions? of course this brings up an
obvious point about our economic system: why is it that Doctors without
Borders, functioning on principle and providing a service for people,
survive only on the generosity of donations, possibly from big nasty
MNC's like Pfizer, while Pfizer (the same one based next to MIT who
prevented affordable AIDS drugs from getting to Africa) can make a
billion bucks off of NSF research grants, a blind eye from the FDA, and
unethical business and medical practices outside and inside US borders?
what kind of values does this economic system encourage by rewarding the
vicious and making life hell for the good-hearted? this case can be
applied to practically all the services nonprofits provide, including my
current environmental one, where we have to beg for money to fix the
environment from government and corporations, while the government pays
corporations and corporations mess up the environment. how do economists
justify this bullshit system of self-destruction--- what, by creating a
problem and fixing it, we increase our GNP (but this is another story)...
